Burkitt Lymphoma of Central Nervous System in an elderly-patient: A new approach with a modified classic regimen


Burkitt Lymphoma of Central Nervous System in an elderly-patient: A new approach with a modified classic regimen


Maria Cynthia Fuentes-Lacouture1, Camila Torres Vélez2, Sergio Alejandro Osorio2, Mariafernanda Gonzalez-Blanco1, Angélica Ovalle2, Juan Sebastian Salas Botero3, Yadira Vasquez3,  Claudia Patricia Niño2, Javier Segovia2

1Medicina Interna, Universidad del Rosario. Hospital Militar Central. Bogotá D.C. Colombia. 2Departamento de Hematología y Oncología. Hospital Militar Central. Universidad Militar Nueva Granada. Bogotá D.C. Colombia. 3Departamento de Patología. Hospital Militar Central. Universidad Militar Nueva Granada. Bogotá D.C. Colombia.


Burkitt’s lymphoma (BL) is one of the high-grade lymphomas, characterized by a rapid growth. They are usually treated with intensive chemotherapy regimens, being normally chemo-sensitive, but at the expense of high toxicity secondary to treatment. Additionally, the compromise of the central nervous system (CNS) implies a major risk as well as greater toxicity, taking into account a worse clinical prognosis with a requirement of more intensive schemes to achieve control of the disease. This implies doubts in the management of older patients with BL with CNS compromise, in whom toxicity is a limitation to these therapies, and there are no other alternatives that offer better benefit in terms of less frequent or severe adverse events, with similar outcomes in terms of progression-free survival (PFS) or overall survival (OS). Therefore, clarifying cases such as the one we report below allows us to provide a therapeutic alternative for older or unfit patients, in whom the intention of treatment should be to seek a good tumor response, but without ignoring the potential toxicity of chemotherapy.


Keywords: Burkitt lymphoma, central nervous system lymphoma, elderly, chemotherapy.

Free Full-text PDF


How to cite this article:

Maria Cynthia Fuentes-Lacouture, Camila Torres Vélez, Sergio Alejandro Osorio, Mariafernanda Gonzalez-Blanco, Angélica Ovalle, Juan Sebastian Salas Botero, Yadira Vasquez, Claudia Patricia Niño, Javier Segovia. Burkitt Lymphoma of Central Nervous System in an elderly-patient:A new approach with a modified classic regimen. International Journal of Case Reports, 2021,5:244. DOI: 10.28933/ijcr-2021-08-1605


References:

1. Kalisz, K., Alessandrino, F., Beck, R., Smith, D., Kikano, E., Ramaiya, N. H., & Tirumani, S. H. (2019). An update on Burkitt lymphoma: a review of pathogenesis and multimodality imaging assessment of disease presentation, treatment response, and recurrence. Insights into imaging, 10(1), 56.
2. Dennis P. O’Malley, Aaron Auerbach, Lawrence M. Weiss; Practical Applications in Immunohistochemistry: Evaluation of Diffuse Large B-Cell Lymphoma and Related Large B-Cell Lymphomas. Arch Pathol Lab Med 1 September 2015; 139 (9): 1094–1107
3. Dunleavy K. Approach to the Diagnosis and Treatment of Adult Burkitt’s Lymphoma. J Oncol Pract. 2018 Nov;14(11):665-671. doi: 10.1200/JOP.18.00148. PMID: 30423267.
4. Adam Zayac, Andrew Matthew Evens, Andrzej Stadnik, Stephen D. Smith, Deepa Jagadeesh, Lori A. Leslie, et al. Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis. Blood 2019; 134.
5. Rausch, C.R., Jabbour, E.J., Kantarjian, H.M. and Kadia, T.M. (2020), Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management. Cancer, 126: 1152-1160.


Terms of Use/Privacy Policy/ Disclaimer/ Other Policies:
You agree that by using our site, you have read, understood, and agreed to be bound by all of our terms of use/privacy policy/ disclaimer/ other policies (click here for details).



This work and its PDF file(s) are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.